A potential best-in-class, bioavailable, oral therapeutic for the treatment of Alcohol Use Disorder (AUD). AUD is a significant public health crisis with a profound unmet need for safer, more effective therapies. When tested against current treatments, our candidate was found to be considerably more effective. Its mechanism has strong clinical validation, with preclinical data demonstrating a significantly improved safety profile alongside robust, dose-dependent efficacy in validated animal models of alcohol consumption. When tested for toxicological effects, it was found to be without any toxicity in rats and dogs. An IND for this candidate was to the FDA in Q4 2025.